Week in SPAC News: ProKidney to merge with Social Capital Suvretta

The Fly

Contributor:
The Fly
Visit: The Fly

DUET acquisition, AIB Acquisition and Technology & Telecommunication Acquisition opened for trading this week.

In SPAC news this week, ProKidney to become public through Social Capital Suvretta combination.

PROKIDNEY, SOCIAL CAPITAL SUVRETTA COMBO: 

ProKidney has entered into a definitive agreement to become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III (DNAC), a special purpose acquisition company. The transaction is expected to deliver up to $825M in gross cash proceeds, including the contribution of up to $250M of cash held in SCS’s trust account, assuming no redemptions by SCS public shareholders, and a fully committed PIPE of $575M. These proceeds will be primarily used to fund React’s Phase 3 development program, accelerate ProKidney’s manufacturing buildout, and ultimately prepare for the global commercial launch of React. The PIPE is led by a $125M contribution from Social Capital, with an additional $50M from ProKidney’s existing investors, approximately $30M from Suvretta Capital’s Averill strategy with the remaining $370M coming from institutional investors and family offices. Existing ProKidney equity holders will roll 100% of their equity into the combined company and will be eligible to receive up to 17.5M additional SCS shares pursuant to an earnout based on ProKidney’s future stock performance. Existing ProKidney shareholders and management have also committed to lock up 50% of their equity interests until the earlier of five years or regulatory market authorization, including full or conditional authorization, to market its lead product candidate, React, subject to certain customary exceptions.

Upon closing of the transaction, the combined company will trade on the Nasdaq under the symbol “PROK.” The transaction, which has been approved by the boards of directors of both SCS and ProKidney and ProKidney’s equity holders, is expected to close in the third quarter of 2022 and is subject to approval by SCS’s shareholders and other customary closing conditions.

LOTTERY OPERATOR ALLWYN IN SPAC DEAL: 

Allwyn Entertainment, a multinational lottery operator, announced its intention to become a publicly-listed company on the NYSE in partnership with NYSE-listed Cohn Robbins (CRHC), resulting in an expected total enterprise value for Allwyn of approximately $9.3B. The transaction provides CRHC shareholders the opportunity to establish ownership stakes at a maximum enterprise value of approximately $8.7B. CRHC is co-chaired by its co-founders, Gary Cohn and Clifton Robbins. The company has identified new market opportunities in Europe and the United States, via potential acquisitions and license tenders, in markets that represent approximately EUR 129B in estimated 2022 lottery wagers. Current Allwyn equity holders are expected to retain approximately 83% ownership in the company, and no new shareholder of the company will own a stake of more than 5% immediately following the transaction. Allwyn’s expected implied pro forma total enterprise value of approximately $9.3B represents approximately 11.5x 2022E adjusted EBITDA. However, due to a bonus pool of up to approximately 6.6M CRHC shares to be made available exclusively to non-redeeming CRHC shareholders, such shareholders have the opportunity to establish ownership stakes at a maximum expected effective valuation multiple of 10.8x 2022E adjusted EBITDA, or approximately $8.7B in total enterprise value. Bonus shares forfeited by redeeming shareholders will be distributed to non-redeeming shareholders on a pro rata basis, which is variable based on a range of exchange ratios for shares held by non-redeeming shareholders of between 1.08x and 1.40x, to be determined based on redemptions.

If the price was $10.00 per share of CRHC common stock at the closing of the transaction, non-redeeming CRHC shareholders would receive, in exchange for each share of CRHC common stock held, shares of the post-combination company with value equating to between $10.80 and $14.00. CRHC, a special purpose acquisition company, holds approximately $828M of cash in trust. Concurrent with the consummation of the proposed transaction, investors have committed to purchase more than $350M of securities of the combined company. The PIPE investment includes participation from a group of international investors, including $50M from CRHC’s sponsor entity. The proposed transaction, which has been unanimously approved by both the board of directors of Allwyn and the board of directors of CRHC, is expected to close in Q2 of 2022, subject to approval by CRHC’s stockholders, gaming regulatory approvals and other customary closing conditions. Upon closing, Robbins will join Allwyn’s board of directors and Cohn will serve as a special advisor to Allwyn’s board chairman.

VISTA, ANGHAMI DEAL APPROVED BY HOLDERS: 

Anghami and Vistas Media Acquisition Company (VMAC) announced that in a special meeting on January 19, 2022, VMAC’s shareholders voted to approve its proposed business combination with Anghami. Approximately 98% of the votes cast at the meeting were in favor of the Business Combination. The Business Combination is expected to close upon satisfaction of the closing conditions. Following the closing of the Business Combination, the common stock and warrants of the surviving company are expected to begin trading on the NASDAQ under the tickers “ANGH” and “ANGHW,” respectively.

SPAC IPOS THIS WEEK:

  • HCM Acquisition (HCMA) opened on January 21 at $10. The company intends to focus on identifying businesses which “provide disruptive technology or innovations within the financial services industry.” The company’s efforts “will be focused on acquiring established businesses that it believes are fundamentally sound, but in need of assistance to maximize their potential value,” HCM said.
  • Heartland Media Acquisition (HMA) opened on January 21 at $10. The company intends to focus on businesses in the media, entertainment and sports sectors. BofA Securities and Moelis & Company are acting as the joint book-running managers for the offering.
  • DUET Acquisition (DUET) opened on January 20 at $9.97. The company intends to focus its search on industries that complement its management team’s background and capitalize on the ability and experience of its management team.
  • AIB Acquisition (AIBB) opened on January 19 at $9.99.
  • Technology & Telecommunication Acquisition (TETE) opened on January 18 at $10. The company intends to focus its search on companies in the technology and telecommunications sector in Malaysia.

Originally Posted on January 23, 2022 – Week in SPAC News: ProKidney to merge with Social Capital Suvretta

Disclosure: Interactive Brokers

Information posted on IBKR Traders’ Insight that is provided by third-parties and not by Interactive Brokers does NOT constitute a recommendation by Interactive Brokers that you should contract for the services of that third party. Third-party participants who contribute to IBKR Traders’ Insight are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.

This material is from The Fly and is being posted with permission from The Fly. The views expressed in this material are solely those of the author and/or The Fly and IBKR is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to sell or the solicitation of an offer to buy any security. To the extent that this material discusses general market activity, industry or sector trends or other broad based economic or political conditions, it should not be construed as research or investment advice. To the extent that it includes references to specific securities, commodities, currencies, or other instruments, those references do not constitute a recommendation to buy, sell or hold such security. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.

In accordance with EU regulation: The statements in this document shall not be considered as an objective or independent explanation of the matters. Please note that this document (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and (b) is not subject to any prohibition on dealing ahead of the dissemination or publication of investment research.

Any trading symbols displayed are for illustrative purposes only and are not intended to portray recommendations.